Comparison · NCT04294667-sae
PBO+SOC vs DZP+SOC: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PBO+SOC vs DZP+SOC: serious adverse events. Trial comparisons, record NCT04294667-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04294667-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.148 | 0.0933 | 0.227 | wilson | |
| Risk in group 2 | 0.0986 | 0.0654 | 0.146 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0496 | -0.023 | 0.135 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.5 | 0.818 | 2.76 | log | |
| Odds ratio, group 1 over group 2 | 1.59 | 0.793 | 3.19 | log | |
| Number needed to harm, for one more participant with a serious adverse event on PBO+SOC than on DZP+SOC | 20.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PBO+SOC | Participants received placebo (PBO) as an intravenous (iv) infusion every 4 weeks (Q4W) in combination with Standard of Care (SOC) during 48 weeks Treatment Period. | 16 | 108 | EG000 |
| Group 2 | DZP+SOC | Participants received Dapirolizumab pegol (DZP) 24 milligrams/kilogram (mg/kg) as an iv infusion Q4W in combination with SOC during 48 weeks Treatment Period. | 21 | 213 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- NCT number
- NCT04294667
- Phases
- PHASE3
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- DZP, Placebo
- Lead sponsor
- UCB Biopharma SRL
- Results first posted
- 2025-04-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04294667?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04294667-sae